Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03355625

Enrollment

Registered

2017-11-28

Start date

2017-09-01

Completion date

2019-11-30

Last updated

2022-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Platelets, Extracorporeal Membrane Oxygenation, Intensive Care Units, Platelet Activation, Platelet Aggregation, Platelet Function Tests

Keywords

Flow Cytometry, eCPR, Extracorporeal Life Support

Brief summary

The primary aim is to describe platelet function in adult patients treated with extracorporeal membrane oxygenation (ECMO). A clarification of the platelet function in these critically ill patients contributes to an understanding of the mechanisms underlying their coagulopathy. The present study is a substudy to the study entitled; Coagulopathy During Extracorporeal Membrane Oxygenation (pending Clinical Trial ID number).

Detailed description

The knowledge of platelet function during extracorporeal membrane oxygenation (ECMO) remains sparse. In the present study, the aim is to investigate platelet function in adult patients treated with ECMO using flow cytometry. The investigators hypothesize that platelet function increases from day 1 to day 3 in patients treated with ECMO. The secondary aim is to investigate the association between platelet function and the incidence of bleeding episodes and thrombosis during ECMO treatment. The present study is a substudy to the study entitled; Coagulopathy During Extracorporeal Membrane Oxygenation (pending Clinical Trial ID number).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Treatment with veno-venous or veno-arterial ECMO * Age ≥18 years

Exclusion criteria

* ECMO treatment initiated post-operatively

Design outcomes

Primary

Measure	Time frame	Description
Changes in platelet function	Platelet function measured day 1 and day 3 on ECMO	Platelet function on day 3 compared with day 1 on ECMO. Measured by flow cytometry

Secondary

Measure	Time frame	Description
Changes in platelet aggregation	Platelet function measured every morning from day 1 to day 8 on ECMO (except weekends).	Comparison of platelet aggregation measured by whole blood impedance aggregometry (Multiplate).
Immature platelet count	Measured every morning from day 1 to day 8 on ECMO (except weekends)	Estimation of platelet turn-over measured by a blood analyzer (Sysmex)
Platelet count	Measured every morning from day 1 to day 8 on ECMO (except weekends)	Estimation of platelet count measured by a blood analyzer (Sysmex)

Countries

Denmark

Outcome results